The company exhibits no scalable revenue-generating activity, with operating losses reaching $3.1 million in 2026Q1 due to heavy R&D spending of $1.4 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | - | - | - | - |
| Cost of Goods Sold | 7.2K | 0 | 27.92K | 25.05K | 40.01K | 69.17K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -7.2K | 0 | -27.92K | -25.05K | -40.01K | -69.17K | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | -11.47% | 37.39% | 42.16% | - | - | - |
| Operating Expenses | 10.06M | 9.07M | 7.98M | 8.66M | 10.86M | 11.95M | 3.8M | 3.64K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.48M | 5.01M | 4.43M | 4.51M | 5.49M | 5.04M | 1.23M | 3.64K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 4.58M | 4.06M | 3.55M | 4.15M | 5.38M | 6.91M | 2.56M | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -10.07M | -9.07M | -7.98M | -8.66M | -10.86M | -11.95M | -3.8M | -3.64K |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -13.74% | 7.87% | 20.32% | 9.09% | -214.83% | -104238.07% | - |
| EBITDA | -10.04M | -9.04M | -7.95M | -8.63M | -10.84M | -11.93M | 0 | -3.64K |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -23.37% | -13.8% | 7.93% | 20.37% | 9.17% | - | 100% | - |
| D&A (Non-Cash Add-back) | 27.04K | 27.06K | 27.92K | 25.05K | 25.05K | 16.78K | 3.8M | 0 |
| EBIT | -10.07M | -9.07M | -7.98M | -8.66M | -10.86M | -11.95M | -3.8M | -3.64K |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | -41.76K | 10.91K | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 10.91K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 41.76K | 0 | 0 |
| Other Income/Expense | 196.71K | 157.16K | -7.06M | 8.54M | 34.96K | -36.35K | 126 | 0 |
| Pretax Income | -9.87M | -8.91M | -15.04M | -120.25K | -10.83M | -11.99M | -3.8M | -3.64K |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -9.87M | -8.91M | -15.04M | -120.25K | -10.83M | -11.99M | -1.63M | -3.64K |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | 31.49% | 40.73% | -12405.64% | 98.89% | 9.65% | -635.16% | -44718.58% | - |
| Net Income (Continuing) | -9.87M | -8.91M | -15.04M | -120.25K | -10.83M | -11.99M | -3.8M | -3.64K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.08 | -23.95 | -87.68 | -8.41 | -9643.37 | -20400.00 | -9032.69 | -6.72 |
| EPS Growth % | 87.19% | 72.68% | -942.57% | 99.91% | 52.73% | -125.85% | -134315.03% | - |
| EPS (Basic) | - | -23.95 | -87.68 | -8.41 | -9643.37 | -20400.00 | -9032.69 | -6.72 |
| Diluted Shares Outstanding | 3.21M | 620.8K | 171.51K | 14.29K | 1.12K | 588 | 181 | 542 |
| Basic Shares Outstanding | 3.21M | 620.8K | 171.51K | 14.29K | 1.12K | 588 | 181 | 542 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Binary clinical trial failure
As indicated by the company's financial disclosures, REVB currently generates no consistent revenue, with the most recent quarterly data showing a complete absence of top-line activity, underscoring the firm's status as a purely clinical-stage entity reliant on external capital rather than operational sales for its ongoing survival.
The intermittent revenue spikes observed in late 2023 and 2024 appear to be non-recurring in nature, likely tied to legacy diagnostic efforts rather than a sustainable commercial pipeline. Investors should monitor the transition from R&D to potential milestone-based revenue, though the current lack of product sales suggests that growth remains entirely speculative and dependent on regulatory success.
Based on reported figures, REVB's cost structure is dominated by research and development expenditures, which reached $1.4 million in 2026Q1, reflecting the high fixed-cost burden inherent in advancing clinical-stage therapeutic candidates through the regulatory pipeline without the benefit of offsetting commercial revenue streams.
The company's expense discipline appears constrained by the necessity of third-party clinical research organization fees, which remain a primary driver of the quarterly cash burn. This reliance on external service providers suggests that operational costs will likely remain elevated and volatile until the company achieves a definitive clinical readout or secures a strategic partnership.
According to historical income statements, REVB exhibits no operating leverage, as the company consistently reports negative operating income, with losses reaching $3.1 million in 2026Q1, a trend that highlights the disconnect between current administrative overhead and the absence of any scalable revenue-generating activities.
The persistent gap between SG&A expenses and the lack of gross profit indicates that the firm is currently in a value-destructive phase of its lifecycle. Without a commercial product to absorb fixed costs, any increase in R&D activity directly exacerbates the operating deficit, necessitating frequent capital raises that dilute existing shareholders.
As evidenced by the company's financial history, the recurring need for equity financing to sustain operations creates a significant overhang, with the most recent quarterly net loss of $3.0 million further depleting the $10.7 million cash reserve and signaling a high probability of future dilutive events.
Short-sellers may focus on the 'going concern' risks inherent in the current burn rate, which suggests that the company's runway is rapidly narrowing. The reliance on at-the-market offerings to fund clinical trials warrants further investigation, as this strategy prioritizes immediate liquidity over the long-term preservation of per-share value for existing investors.
Quick answers to the most common questions about buying REVB stock.
For fiscal year 2025, Revelation Biosciences, Inc. (REVB) reported total revenue of $0.0M.
Revelation Biosciences, Inc. (REVB) reported a net loss of $8.9M for the fiscal year ending 2025.